CSIMarket
 
Maravai Lifesciences Holdings Inc   (NASDAQ: MRVI)
Other Ticker:  
 
 
Price: $2.0700 $0.06 2.985%
Day's High: $2.115 Week Perf: -1.43 %
Day's Low: $ 1.99 30 Day Perf: -12.66 %
Volume (M): 1,144 52 Wk High: $ 11.56
Volume (M$): $ 2,368 52 Wk Avg: $6.50
Open: $2.05 52 Wk Low: $1.68



 Market Capitalization (Millions $) 286
 Shares Outstanding (Millions) 138
 Employees 1,338
 Revenues (TTM) (Millions $) 259
 Net Income (TTM) (Millions $) -260
 Cash Flow (TTM) (Millions $) -253
 Capital Exp. (TTM) (Millions $) 31

Maravai Lifesciences Holdings Inc
Maravai Lifesciences Holdings Inc is a global life sciences company that develops and provides critical products and services to the biopharmaceutical, diagnostic, and broader life sciences industries. The company was founded in 2014 and is headquartered in San Diego, California, United States.

The company operates through two business segments: Contract Development & Manufacturing Organization (CDMO) and Life Sciences.

The CDMO segment provides development and manufacturing services for gene therapy and vaccine products, as well as diagnostic and other biologics products. Its services include process development, cell line development, clinical and commercial manufacture, and testing and analytics.

The Life Sciences segment includes three business units: Genomics, Diagnostics, and Protein Sciences. The Genomics unit provides nucleic acid isolation and purification products, as well as other sample collection and preparation products for genetic sequencing applications. The Diagnostics unit develops and manufactures an array of diagnostic kits and reagents, and also provides custom contract development services. The Protein Sciences unit provides research and diagnostic tools for protein analysis.

Maravai has a global presence, with facilities in the United States, Europe, and Asia-Pacific. The company's clients include leading biopharmaceutical, research, academic and diagnostic organizations.

The company has been experiencing significant growth over the past few years, driven by strong demand for its products and services, as well as its focus on innovation and strategic acquisitions. In September 2020, Maravai completed its initial public offering (IPO), raising $62 billion USD in gross proceeds.

Overall, Maravai Lifesciences Holdings Inc is a highly respected and innovative company in the life sciences industry, dedicated to delivering high-quality, critical products and services to its clients worldwide.


   Company Address: 10770 Wateridge Circle San Diego 92121 CA
   Company Phone Number: 546-0004   Stock Exchange / Ticker: NASDAQ MRVI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANAB        3.72% 
GRI        5.99% 
A        0.53% 
BIO   -2.62%    
ILMN        1.11% 
QGEN        0.73% 
• View Complete Report
   



Announcement

Legal Turmoil for Maravai LifeSciences Shareholder Lawsuits Spark Concern Amidst Investor Discontent

Published Tue, Apr 29 2025 9:16 AM UTC

Legal Turmoil for Maravai LifeSciences: Shareholder Lawsuits Spark Concern Amidst Investor Discontent In recent weeks, Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has found itself embroiled in a series of legal challenges that have sent ripples through the investment community. With multiple law firms announcing class action lawsuits against the company, shareholders ...

Announcement

Maravai LifeSciences Holdings, Inc. Sued for Securities Violations as Company Reports Stagnant Revenue Compared to ...

Published Wed, Apr 23 2025 7:00 PM UTC

Maravai LifeSciences Holdings, Inc. Faces Legal Troubles Amid Lackluster Financial PerformanceOn April 23, 2025, Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) found itself embroiled in a legal controversy as The Gross Law Firm issued a notice to its shareholders regarding potential securities law violations. This announcement invites shareholders to discuss their right...

Announcement

Maravai LifeSciences Holdings A Financial Analysis Amid Class Action Investigation

Published Thu, Apr 10 2025 9:25 AM UTC

In recent developments, Bronstein, Gewirtz & Grossman LLC has announced its intention to lead a class action lawsuit for investors of Maravai LifeSciences Holdings, Inc. who have incurred substantial losses. This announcement arrives during a pivotal moment for the company, which has displayed a complex financial performance in its latest quarterly report.Maravai LifeScience...

Announcement

Multiple Law Firms Mobilize to Represent Maravai LifeSciences Investors Amid Class Action Lawsuit

Published Thu, Apr 10 2025 6:17 AM UTC

Maravai LifeSciences Holdings, Inc.: A Crucial Moment for Investors as Class Action Lawsuits Progress In recent weeks, investors in Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) have faced significant turmoil as a class action lawsuit has been initiated against the company and its executives. As outlined in announcements from respected law firms, including Bronstein, Ge...

Announcement

Maravai LifeSciences Holdings Inc. Faces Legal Turmoil A Deep Dive into Recent Securities Concerns

Published Mon, Apr 7 2025 6:32 PM UTC

The landscape of pharmaceutical investments can be as unpredictable as the market itself. Nowhere is this more evident than with Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), which has recently found itself embroiled in a class action lawsuit that could significantly affect its stock performance. Levi & Korsinsky LLP, a law firm known for advocating for investors, has ...







Maravai Lifesciences Holdings Inc's Segments
North America    53.21 % of total Revenue
Europe the Middle East and Africa    11.45 % of total Revenue
Asia Pacific    35.15 % of total Revenue
Latin and Central America    0.19 % of total Revenue
Nucleic Acid Production    76.61 % of total Revenue
Nucleic Acid Production North America    42.49 % of total Revenue
Nucleic Acid Production Europe the Middle East and Africa    6.12 % of total Revenue
Nucleic Acid Production Asia Pacific    27.93 % of total Revenue
Nucleic Acid Production Latin and Central America    0.07 % of total Revenue
Biologics Safety Testing    23.39 % of total Revenue
Biologics Safety Testing North America    10.72 % of total Revenue
Biologics Safety Testing Europe the Middle East and Africa    5.33 % of total Revenue
Biologics Safety Testing Asia Pacific    7.22 % of total Revenue
Biologics Safety Testing Latin and Central America    0.12 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com